Linked Life Data

17400067

Source:http://linkedlifedata.com/resource/pubmed/id/17400067

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2007-4-2
pubmed:abstractText
Our group has previously reported that a significantly larger proportion of peripheral monocytes from human immunodeficiency virus type 1 (HIV-1) seropositive individuals receiving highly active antiretroviral therapy (HAART) express HLA-G1 and also that one of the HAART components, the nucleoside reverse transcriptase inhibitors (NRTIs), may be involved in this effect. Because protease inhibitors (PIs) are another component of HAART that are administered with NRTIs, the aim of this work was to determine whether or not PIs are also involved in the HLA-G1 changes previously observed in treated HIV-1 positive patients. CD14(+) cells expressing HLA-G1 were therefore measured in 7 HIV-1 positive patients whose initial HAART was changed to a protease inhibitor-only regime due to drug toxicity and/or virologic resistance. Our results indicate that PIs do not appear to be implicated in the rise of HLA-G1 expression on CD14(+) cells from HIV-1 infected individuals receiving HAART, while we further confirm that NRTIs are involved in the surface induction of HLA-G1.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0198-8859
pubmed:author
pubmed:issnType
Print
pubmed:volume
68
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
303-6
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Nucleoside reverse transcriptase inhibitors are able and protease inhibitors unable to induce the tolerogenic molecule HLA-G1 on monocytes from HIV-1 infected patients.
pubmed:affiliation
Infectious Unit, Reina Sofía University Hospital, Córdoba, Spain.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't